GENE ONLINE|News &
Opinion
Blog

2020-12-18| In-DepthSpecial

Coexistence of Thrombophilic Factors and Hemophilia – A Blessing in Disguise?

by GeneOnline
Share To
The most common treatment for hemophilia is a factor replacement therapy, but it comes with challenges like frequent infusions, cost, development of inhibitors, etc. To overcome these limitations, new approaches were explored, such as factors with an extended half-life, inhibition of anticoagulant proteins, and gene therapy.
In normal circumstances, the coexistence of two disorders would enhance distress in an already suffering individual, but what would happen if thrombophilia and hemophilia coexist in an individual? Will they complement each other?

GO Prime with only $1.49 now

LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top